<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01573143</url>
  </required_header>
  <id_info>
    <org_study_id>2.0 /06.09.11</org_study_id>
    <nct_id>NCT01573143</nct_id>
  </id_info>
  <brief_title>Statin Therapy In Cardiac Surgery</brief_title>
  <acronym>STICS</acronym>
  <official_title>Statin Therapy In Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of STICS trial (Statin Therapy In Cardiac Surgery) is to test whether
      perioperative treatment with Rosuvastatin 20 mg once daily prevents post-operative atrial
      fibrillation and reduces perioperative irreversible myocardial damage in patients undergoing
      elective cardiac surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evidence that pre- or perioperative statin treatment may reduce the occurrence of
      post-operative atrial fibrillation and improve clinical outcome in patients undergoing
      coronary artery bypass graft (CABG) or major vascular surgery has been largely generated by
      observational studies. In a recent meta-analysis of 6 randomized trials (of which only 2 had
      postoperative atrial fibrillation (AF) as a predefined outcome) evaluating the use of
      perioperative statin treatment in patients undergoing cardiac surgery (n=651 patients in
      total - study size between 40 and 200 patients), statin use was found to reduce the patients'
      relative risk of developing postoperative AF by 43% (RR 0.57, 95%CI 0.45,0.72) and their
      absolute risk by 14% (95% CI 8%,20%). Although these findings would be consistent with a
      rapid and, possibly, lipid-independent antiarrhythmic effect of statins, they have important
      limitations (e.g., single-centre, small size, lack of continuous ECG monitoring, mostly
      &quot;ancillary&quot; findings&quot;) and less bearing on current clinical practice, as they mostly included
      statin-naïve patients. For these reasons, the recent guidelines for the management of AF have
      not given a strong recommendation for the use of statins in the prevention of postoperative
      AF. Thus, whether intensive statin treatment in the perioperative period is associated with
      prevention of AF, cardio protection, and improved clinical outcome remains to be
      demonstrated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post operative atrial fibrillation detected on continuous ECG monitoring.</measure>
    <time_frame>Monitoring will commence soon after surgery and will be continued until the end of post operative day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial injury assessed by Troponin release</measure>
    <time_frame>Serial blood samples for Troponin assay will be collected at 6, 24, 48 and 120 hours after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital and intensive care unit stay</measure>
    <time_frame>Participants will be followed for the duration of the post operative period up to the day of initial discharge from the hospital, an expected average of 7 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major in-hospital cardiac and/or cerebrovascular events (such as death, stroke, myocardial infarction,heart failure) and acute kidney injury</measure>
    <time_frame>Participants will be followed for the duration of the post operative period up to the day of initial discharge from the hospital, an expected average of 7 days.</time_frame>
    <description>Outcomes will be monitored for their presence/absence (Yes/No), the post operative day of event and duration as applicable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac tissue and plasma/ urine biomarkers</measure>
    <time_frame>Post operative period including day 5</time_frame>
    <description>Cardiac tissue and plasma/ urine biomarkers of inflammation, oxidant stress, and cardiac function</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1922</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Myocardium; Injury</condition>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin (20 mg od)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Rosuvastatin (20 mg od) started not earlier than 8 days before surgery and continued until the 5th post-operative day included;</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo started not earlier than 8 days before surgery and continued until the 5th post-operative day included.</description>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients awaiting elective cardiac surgery who are willing and able to give
             informed consent for participation in the study and who are in sinus rhythm and not
             taking any antiarrhythmic medication, other than beta-adrenergic blocking agents, at
             the time of surgery.

        Exclusion Criteria:

          -  History of obstructive hepato-biliary disease or other serious hepatic disease

          -  Untreated hypothyroidism

          -  Creatinine &gt; 200 umol/L

          -  Personal and family history of hereditary muscle disorders

          -  Known intolerance to statins or history of muscle toxicity with fibrates or statins.

          -  On-going use of fibrates, niacin or of agents that are strong inhibitors of cytochrome
             P-450 or the P-glycoprotein within a month preceding randomization (cyclosporine, oral
             azole antifungals,macrolide antibiotics, protease inhibitors, nefazodone, amiodarone
             or ≥ 1L/day of grapefruit juice)

          -  Significant mitral valve disease (moderate or severe mitral regurgitation-eg. &gt; grade
             II and/or mitral stenosis &amp; mitral annular calcification).

          -  Patients treated with any anti-arrhythmic agent (other than beta-adrenergic receptor
             blockers).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rory Collins, FRCP. FMed Sci</last_name>
    <role>Study Chair</role>
    <affiliation>Clinical Trial Service Unit (CTSU), University of Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shenshou Hu, MD.PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fuwai Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara Casadei, MD.DPhil.FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiovascular Medicine, John Radcliffe Hospital, University of Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zheng Zhe, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuwai Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fuwai Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Laufs U, Kilter H, Konkol C, Wassmann S, Böhm M, Nickenig G. Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc Res. 2002 Mar;53(4):911-20.</citation>
    <PMID>11922901</PMID>
  </reference>
  <reference>
    <citation>Maack C, Kartes T, Kilter H, Schäfers HJ, Nickenig G, Böhm M, Laufs U. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation. 2003 Sep 30;108(13):1567-74. Epub 2003 Sep 8.</citation>
    <PMID>12963641</PMID>
  </reference>
  <reference>
    <citation>Kim YM, Guzik TJ, Zhang YH, Zhang MH, Kattach H, Ratnatunga C, Pillai R, Channon KM, Casadei B. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res. 2005 Sep 30;97(7):629-36. Epub 2005 Aug 25.</citation>
    <PMID>16123335</PMID>
  </reference>
  <reference>
    <citation>Kim YM, Kattach H, Ratnatunga C, Pillai R, Channon KM, Casadei B. Association of atrial nicotinamide adenine dinucleotide phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery. J Am Coll Cardiol. 2008 Jan 1;51(1):68-74. doi: 10.1016/j.jacc.2007.07.085.</citation>
    <PMID>18174039</PMID>
  </reference>
  <reference>
    <citation>European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010 Oct;31(19):2369-429. doi: 10.1093/eurheartj/ehq278. Epub 2010 Aug 29. Erratum in: Eur Heart J. 2011 May;32(9):1172.</citation>
    <PMID>20802247</PMID>
  </reference>
  <reference>
    <citation>Chen WT, Krishnan GM, Sood N, Kluger J, Coleman CI. Effect of statins on atrial fibrillation after cardiac surgery: a duration- and dose-response meta-analysis. J Thorac Cardiovasc Surg. 2010 Aug;140(2):364-72. doi: 10.1016/j.jtcvs.2010.02.042. Epub 2010 Apr 9. Review.</citation>
    <PMID>20381820</PMID>
  </reference>
  <reference>
    <citation>Reilly SN, Jayaram R, Nahar K, Antoniades C, Verheule S, Channon KM, Alp NJ, Schotten U, Casadei B. Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins. Circulation. 2011 Sep 6;124(10):1107-17. doi: 10.1161/CIRCULATIONAHA.111.029223. Epub 2011 Aug 15.</citation>
    <PMID>21844076</PMID>
  </reference>
  <reference>
    <citation>Antoniades C, Bakogiannis C, Leeson P, Guzik TJ, Zhang MH, Tousoulis D, Antonopoulos AS, Demosthenous M, Marinou K, Hale A, Paschalis A, Psarros C, Triantafyllou C, Bendall J, Casadei B, Stefanadis C, Channon KM. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation. 2011 Jul 19;124(3):335-45. doi: 10.1161/CIRCULATIONAHA.110.985150. Epub 2011 Jul 5.</citation>
    <PMID>21730307</PMID>
  </reference>
  <reference>
    <citation>Antoniades C, Demosthenous M, Reilly S, Margaritis M, Zhang MH, Antonopoulos A, Marinou K, Nahar K, Jayaram R, Tousoulis D, Bakogiannis C, Sayeed R, Triantafyllou C, Koumallos N, Psarros C, Miliou A, Stefanadis C, Channon KM, Casadei B. Myocardial redox state predicts in-hospital clinical outcome after cardiac surgery effects of short-term pre-operative statin treatment. J Am Coll Cardiol. 2012 Jan 3;59(1):60-70. doi: 10.1016/j.jacc.2011.08.062.</citation>
    <PMID>22192670</PMID>
  </reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2012</study_first_submitted>
  <study_first_submitted_qc>April 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2012</study_first_posted>
  <last_update_submitted>September 16, 2014</last_update_submitted>
  <last_update_submitted_qc>September 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Surgical Procedures, Cardiac</keyword>
  <keyword>Hydroxymethylglutaryl-CoA Reductase Inhibitors</keyword>
  <keyword>Rosuvastatin</keyword>
  <keyword>Post operative atrial fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

